Skip to main content

Drug Interactions between Leukine and Pomalyst

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sargramostim pomalidomide

Applies to: Leukine (sargramostim) and Pomalyst (pomalidomide)

Using sargramostim during or too soon after completion of a course of pomalidomide may alter the effects of either medication. Sargramostim should generally not be given within 24 hours before or 24 hours after cancer chemotherapy. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

pomalidomide food

Applies to: Pomalyst (pomalidomide)

If you are a smoker, you should be aware that cigarette smoking may reduce the blood levels and effects of pomalidomide. Talk to your health care professional if you have any questions or concerns. Pomalidomide should be taken with water the same time everyday on an empty stomach, at least 2 hours before or 2 hours after a meal. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.